PMID- 19223493
OWN - NLM
STAT- MEDLINE
DCOM- 20090414
LR  - 20221207
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 15
IP  - 5
DP  - 2009 Mar 1
TI  - Overexpression of phosphorylated mammalian target of rapamycin predicts lymph 
      node metastasis and prognosis of chinese patients with gastric cancer.
PG  - 1821-9
LID - 10.1158/1078-0432.CCR-08-2138 [doi]
AB  - PURPOSE: We determined the expression of mammalian target of rapamycin (mTOR) and 
      its activated form, p-mTOR, in Chinese patients with gastric cancer and its 
      clinical effects and underlying mechanisms. EXPERIMENTAL DESIGN: Tissue 
      microarray blocks containing gastric cancer tissue and matched noncancer gastric 
      tissue specimens obtained from 1,072 patients were constructed. Expression of 
      total mTOR and p-mTOR in these specimens was analyzed using immunohistochemical 
      studies and confirmed by Western blotting. RESULTS: The overall rates of total 
      mTOR and p-mTOR overexpression were 50.8% (545 of 1,072) and 46.5% (499 of 
      1,072), respectively. The p-mTOR overexpression was significantly correlated with 
      total mTOR overexpression. Overexpression of total mTOR protein was significantly 
      correlated with tumor differentiation, T1/T2 tumors, and stage I/II/III disease, 
      whereas p-mTOR overexpression was significantly correlated with lymph node 
      metastasis and all stage disease. The Cox proportional hazards model revealed 
      that the overexpression of p-mTOR, but not total mTOR, was an independent 
      prognostic factor for gastric cancer. The overexpression of p-mTOR also predicted 
      the angiogenic phenotype of human gastric cancer and regulated angiogenesis of 
      gastric cancer cells. CONCLUSIONS: Increased activation of mTOR is frequent in 
      human gastric cancer and overexpression of p-mTOR is an independent prognostic 
      factor, suggesting that mTOR pathway could be a potential target for therapy of 
      this malignancy.
FAU - Yu, Guanzhen
AU  - Yu G
AD  - Department of Medical Oncology, Changzheng Hospital, Shanghai, People's Republic 
      of China.
FAU - Wang, Jiejun
AU  - Wang J
FAU - Chen, Ying
AU  - Chen Y
FAU - Wang, Xi
AU  - Wang X
FAU - Pan, Jun
AU  - Pan J
FAU - Li, Gang
AU  - Li G
FAU - Jia, Zhiliang
AU  - Jia Z
FAU - Li, Qiang
AU  - Li Q
FAU - Yao, James C
AU  - Yao JC
FAU - Xie, Keping
AU  - Xie K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090217
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (mTOR protein, mouse)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adenocarcinoma/*metabolism/secondary
MH  - Adenocarcinoma, Mucinous/*metabolism/secondary
MH  - Animals
MH  - Asian People
MH  - Blotting, Western
MH  - Carcinoma, Papillary/*metabolism/secondary
MH  - Carcinoma, Signet Ring Cell/*metabolism/secondary
MH  - Cells, Cultured
MH  - Endothelium, Vascular
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Liver Neoplasms/*metabolism/secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic
MH  - Phosphorylation
MH  - Prognosis
MH  - Protein Kinases/*metabolism
MH  - Stomach Neoplasms/*metabolism/pathology
MH  - Survival Rate
MH  - TOR Serine-Threonine Kinases
MH  - Tissue Array Analysis
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Xenograft Model Antitumor Assays
EDAT- 2009/02/19 09:00
MHDA- 2009/04/15 09:00
CRDT- 2009/02/19 09:00
PHST- 2009/02/19 09:00 [entrez]
PHST- 2009/02/19 09:00 [pubmed]
PHST- 2009/04/15 09:00 [medline]
AID - 1078-0432.CCR-08-2138 [pii]
AID - 10.1158/1078-0432.CCR-08-2138 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2009 Mar 1;15(5):1821-9. doi: 10.1158/1078-0432.CCR-08-2138. 
      Epub 2009 Feb 17.